Compound as KCNQ potassium channel agonist, preparation method therefor and use thereof

US9353048B2 · kind B2 · utility

Assignee

• SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN

Inventors

• Fajun Nan · Shanghai, CN
• Min Li · New Orleans, US
• Zhaobing GAO · Shanghai, CN
• Fei-Yun Chen · Shanghai, CN
• Yangming Zhang · Shanghai, CN
• Pingzheng Zhou · Shanghai, CN
• Haining Hu · Shanghai, CN
• Haiyan Xu · Beijing, CN
• Sheng Liu · San Jose, US

Key dates

• Filing date: Oct 23, 2012
• Grant date: May 31, 2016
• Expiry date: Oct 23, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D235/26
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.